Quoi de neuf ?
Quoi de neuf en ce moment chez Dr. Falk Pharma AG ? Vous trouverez les actualités, les communiqués de presse, les appels à études et les évènements à venir dans notre Newsroom et sur les réseaux sociaux.
New Addition to the Management Board
The new Technical Operations business unit will be headed up by Dr. Andreas Rascher
En savoir plus
Eating should be a pleasure
What does it feel like to eat when you know that each bite will hurt when swallowing?
En savoir plus
Management change at Dr. Falk Pharma GmbH
Kai Pinkernell takes over as Managing Director Science & Innovation.
En savoir plus
Rare Disease Day
As the experts in digestive and metabolic medicine, our focus is also on rare diseases.
En savoir plus
Initiation of Phase II Study of naronapride in patients with gastroparesis
Renexxion Ireland and Dr. Falk Pharma announce that the first patient has been treated
En savoir plus
Launch of Dr. Falk Pharma in Italy
We are pleased to introduce our Italian affiliate!
En savoir plus
Collaboration and Licensing Agreement with Takeda and Zedira
To Develop First-in-Class Celiac Disease Therapy
En savoir plus
Launch of Dr. Falk Pharma in France
We are pleased to introduce our French affiliate!
En savoir plus
NAFLD: Phase 2a proof of concept study of ZED1227
Dr. Falk Pharma and Zedira announce trial start for the treatment of non-alcoholic fatty liver disease. First patient enrolled in April.
En savoir plus
Have difficulty swallowing food?
Difficulty swallowing and pain while eating may be warning signs of eosinophilic esophagitis (EoE). The first EoE Day will be held on May 22, 2022.
En savoir plus
Future starts here
Plans for the future Falk Campus in Freiburg-Nord finalized.
En savoir plus